Precision Cannabinoid Therapeutics
Mitzva Wellness Precision
Cannabinoid Therapeutics BHC’s acquisition of a boutique Kosher CBD Brand is best known for
treatment of Autism and other neurological indications.
BHC’s Science Advisory Board, led by world renowned endocannabinoid researcher, Alexandros Makriyannis, Ph.D. and with expertise of BHC, the Mitzva brand has evolved. Therapeutic based cannabinoids and terpene profiles will sustain revenues by expanding product line utilizing digital educational and promotion campaigns.